8月13日，康希諾生物股份公司（以下簡稱“康希諾生物”）成功登陸科創板，成為首個“A+H”疫苗股?？迪ＶZ生物（康希諾688185.SH，康希諾生物06185.HK）此次科創板公開發行股票數量為2480萬股，發行價格為209.71元。

募集資金將用于生產基地二期建設、在研疫苗研發、疫苗追溯、冷鏈物流體系及信息系統建設及補充流動資金。

康希諾生物董事長、首席執行官宇學峰博士表示：“上海證券交易所推出科創板及香港聯交所上市制度改革，對于前期投入規模大、周期長，需要持續獲得資金推進研發的生物醫藥企業，都是極為重要的政策支持，對于企業品牌價值的提升，及立足中國進行全球化戰略布局具有積極意義。我們將一如既往地堅持以研發、生產和商業化高質量、創新及可負擔的疫苗為己任，為中國乃至全球公共衛生水平的提升做出貢獻?！?

康希諾生物以在世界范圍內提供預防傳染病和感染病的解決方案為目標，專業從事高質量人用疫苗的研發、生產和商業化，在一大批疫苗領域的知名科學家和資深技術專家的帶領下，建立了基于腺病毒載體疫苗技術、蛋白結構設計和重組技術、結合技術和制劑技術等四大核心技術平臺，擁有多項疫苗核心知識產權及專有技術。

依托上述技術平臺，康希諾生物開展針對腦膜炎、埃博拉病毒病、百白破、肺炎、結核病、新型冠狀病毒（COVID-19）、帶狀皰疹等13個適應癥研發16種重磅疫苗，并快速推進在研管線產品的開發。

其中，康希諾生物與軍事科學院軍事醫學研究院生物工程研究所（以下簡稱“軍科院生物工程研究所”）合作研發的重組埃博拉病毒病疫苗（腺病毒載體）已獲得新藥注冊批準，是中國獨立研發、具有完全自主知識產權的全球創新疫苗產品。兩款在研腦膜炎球菌結合疫苗已臨近商業化，國內首創的四價腦膜炎球菌結合疫苗已獲得國家藥品監督管理局新藥注冊優先審評資格。

2020年3月，康希諾生物與軍科院生物工程研究所聯合研發的重組新型冠狀病毒疫苗（腺病毒載體）成為全球率先進入臨床研究階段的新冠候選疫苗，目前已完成二期臨床試驗，并獲得中央軍委后勤保障部衛生局頒發的軍隊特需藥品批件，有效期一年，可在軍隊內部使用。

此外，康希諾生物的重組肺炎蛋白疫苗、13價肺炎球菌結合疫苗、嬰幼兒組分百白破疫苗、結核病加強疫苗等多種創新疫苗處在臨床試驗階段，另有六款候選疫苗處在臨床前研究階段。全面的疫苗管線將為后續的持續盈利能力提供堅實的保障,市場期待著康希諾生物對標國際質量標準的疫苗產品陸續問世，實現為中國及全球提供創新、優質、可及疫苗的使命。

關于康希諾生物

康希諾生物股份公司（H股簡稱：康希諾生物，代碼06185.HK；A股簡稱：康希諾，代碼688185.SH），2009年成立于中國天津，致力于為中國及全球公共衛生研發、生產和商業化創新疫苗。公司現有四個創新疫苗平臺技術，包括腺病毒載體疫苗技術、結合技術、蛋白設計與重組技術、制劑技術。目前，公司已建立覆蓋13種傳染病的16種疫苗的強大研發管線，其中包括2017年獲得批準的全球創新重組埃博拉病毒病疫苗以及目前在研的重組新型冠狀病毒疫苗（腺病毒載體）。

FOR IMMEDIATE RELEASE

CanSinoBIO’s Successful Listing on STAR MarketMakes it the Initial Dual Listing Vaccine Company

SHANGHAI, CHINA, August 13, 2020,CanSino Biologics Inc. (“CanSinoBIO”) (SHSE: 688185, HKEX:06185) announced today that it has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+ H" dual listing vaccine company. CanSinoBIO will issue 24.8 million shares at the issue price of RMB209.71 per Share.

The funds will provide full support to the construction of the second phase manufacturing facility, vaccine research and development, vaccine traceability, the construction of cold chain logistics system and information system, as well as the supplementary working capital.

Dr. Xuefeng Yu, chairman and chief executive officer of CanSinoBIO, said: "The launch of STAR Market and the reform of HKEX listing have provided policy support for biopharmaceutical companies that require continuous long-term, large-scale investments for research and development of vaccine candidates. It allows companies to have branding benefits and make global strategic plans. We will continue being committed to making the innovative and affordable high-quality vaccines accessible to people and contributing to the improvement of public health worldwide."

With the goal of providing solutions to prevent infectious diseases globally, CanSinoBIO is dedicated to the research, development, manufacturing and commercialization of high-quality vaccines for human use. Led by a team of accomplished scientists and experienced experts in the field of vaccines, CanSinoBIO has developed four key platform technologies, including adenovirus-based viral vector vaccine, conjugation, protein structure design and recombination as well as vaccine formulation technologies. In addition, it has in-licensed a number of core intellectual properties.

CanSinoBIO is currently developing 16 vaccine candidates for 13 infectious disease areas, including meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc.

Among them, the recombinant Ebola virus vaccine (Ad5-EBOV), jointly developed by CanSinoBIO and the Beijing Institute of Biotechnology, Academy of Military Medical Sciences (BIB), has obtained the approval in China. The two meningococcal conjugate vaccines under research are close to commercialization, among which the quadrivalent meningococcal conjugate vaccine is the first of its kind in China that has been granted priority review designation by the China National Medical Products Administration (NMPA).

In March 2020, the Recombinant Novel Coronavirus Vaccine (the “Ad5-nCoV”), a vaccine candidate co-developed by CanSinoBIO and BIB, became the world's initial vaccine candidate to enter the clinical research stage. The two phases of the clinical trial has now been completed and the results had already been published on the Lancet journal. In June, the vaccine received China’s military specially-needed drug approval with a valid period for one year.

In addition, the Pneumococcal vaccine portfolio, DTcP vaccine portfolio, TB Booster and several other innovative vaccines are currently under clinical trial stage or pre-clinical research stage. The comprehensive vaccine product pipeline will not only ensure the continuous profitability in the near future, but will also help realize the mission of providing innovative, high-quality and accessible vaccines for China and the world.

About CanSinoBIO

Incorporated in 2009, CanSinoBIO (SHSE: 688185, HKEX:06185) commits to research, production and commercialization of innovative vaccines for China and global public health security. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 16 vaccines preventing 13 diseases, including a globally innovative Ebola virus vaccine approved in 2017 as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector). Additional information can be found online at www.cansinotech.com